Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4811 | washed microbiota transplantation Wiki | 0.71 |
| drug104 | ADM03820 Wiki | 0.71 |
| drug4148 | Unfractionated heparin nebulized Wiki | 0.71 |
Navigate: Correlations HPO
There are 2 clinical trials
Hypercoagulability has been demonstrated in COVID-19, leading to respiratory distress and increased mortality. This is adaptive clinical trial to compare effectiveness and safety of four therapeutic strategies in hospital mortality in patients with COVID-19: standard prophylaxis, therapeutic dose anticoagulation, inhaled UFH associated with standard prophylaxis and ASA associated with standard prophylaxis.
Description: Number of COVID-19 positive patients who are alive within 30 days of symptoms onset
Measure: Hospital discharge - alive / death Time: 30 daysDescription: Comparison of length of mechanical ventilation free days between each treatment arm
Measure: Length of mechanical ventilation free days Time: 30 daysDescription: Comparison of length of renal replacement therapy free days between each treatment arm
Measure: Length of renal replacement therapy free days Time: 30 daysDescription: Comparison of number of thrombosis events between each treatment arm.
Measure: Number of documented venous thromboembolism or arterial thrombosis Time: 3 monthsSince the emergence of the new strain of betacoronavirus (SARS-CoV-2) and its important clinical repercussions, it has been described that patients with its associated pneumonia (COVID-19) have high rates of thrombotic events, including reduction in the dialyzers patency when undergoing renal replacement therapy. Several strategies for preventing the early loss of dialysers are described, and regional anticoagulation based on citrate is the preferred modality for preventing this complication. On the other hand, in patients with SARS-CoV-2 there are already descriptions of endothelial inflammation and activation of the coagulation cascade, including studies demonstrating the benefit of heparinization of these patients. Thus, this study aims to compare two different anticoagulation strategies in patients infected with COVID-19 with continued venovenous hemodialysis (CVVHD). From the indication of CVVHD, patients will be screened according to eligibility criteria and, if they fit these parameters, they will be randomized into two groups: Group A - Standard regional anticoagulation based on Citrate associated with infusion of low doses of unfractionated heparin 10ui/kg/hour and Group B - Standard regional anticoagulation based on Citrate only. Patients will be randomized in blocks and followed for 72 hours. The primary endpoint is dialyzer patency at the end of 72 hours of clinical follow-up. Secondary objectives will be mortality, bleeding rate, drop in hematimetric indices, urea sieving, filter time in hours, down time of therapy, system and dialyser pressures (PBE and PTM). All patients will undergo a standard procedure with a prescribed dose of 30mL/Kg/H, blood flow of 150mL/minute and polysulfone dialyzer.
Description: The percentage of clotted dialyzers within 72 hours in each of the studied groups.
Measure: Clotted dialyzers Time: Day 3 of dialysisDescription: Number of hours until a dialyzer clots in the first 72 hours of dialysis
Measure: Time-free of clotting Time: Day 3 of dialysisDescription: The amount of dialyzers used in the first 72 hours of hemodialysis
Measure: Number of dialyzers used Time: Day 3 of dialysisDescription: Variation in dialysis system and vascular access pressures in the first 72 h of dialysis
Measure: Pressure variation Time: Day 3 of dialysisDescription: Variation in urea sieving between the first, second and third days of dialysis
Measure: Urea sieving Time: Day 3 of dialysisDescription: Time of dialysis stop due to clotting in the first 72 hours
Measure: Downtime of dialysis Time: Day 3 of dialysisAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports